These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 27483215)

  • 1. Native Mass Spectrometry in Fragment-Based Drug Discovery.
    Pedro L; Quinn RJ
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.
    Williams G; Ferenczy GG; Ulander J; Keserű GM
    Drug Discov Today; 2017 Apr; 22(4):681-689. PubMed ID: 27916639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the Exactive Plus EMR for automated protein-ligand screening by non-covalent mass spectrometry.
    Maple HJ; Scheibner O; Baumert M; Allen M; Taylor RJ; Garlish RA; Bromirski M; Burnley RJ
    Rapid Commun Mass Spectrom; 2014 Jul; 28(13):1561-8. PubMed ID: 24861608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Native ESI-MS to Characterize Interactions between Compounds Derived from Fragment-Based Discovery Campaigns and Two Pharmaceutically Relevant Proteins.
    Gavriilidou AFM; Holding FP; Coyle JE; Zenobi R
    SLAS Discov; 2018 Oct; 23(9):951-959. PubMed ID: 29852073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of (19)F-NMR in Fragment-Based Drug Discovery.
    Norton RS; Leung EW; Chandrashekaran IR; MacRaild CA
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of native mass spectrometry in characterizing the structure and dynamics of macromolecular complexes.
    Boeri Erba E; Petosa C
    Protein Sci; 2015 Aug; 24(8):1176-92. PubMed ID: 25676284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Determination of Protein-Ligand Affinity by Size Exclusion Chromatography Directly Coupled to High-Resolution Native Mass Spectrometry.
    Ren C; Bailey AO; VanderPorten E; Oh A; Phung W; Mulvihill MM; Harris SF; Liu Y; Han G; Sandoval W
    Anal Chem; 2019 Jan; 91(1):903-911. PubMed ID: 30481450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches for computing ligand-receptor binding kinetics.
    Bruce NJ; Ganotra GK; Kokh DB; Sadiq SK; Wade RC
    Curr Opin Struct Biol; 2018 Apr; 49():1-10. PubMed ID: 29132080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native State Mass Spectrometry, Surface Plasmon Resonance, and X-ray Crystallography Correlate Strongly as a Fragment Screening Combination.
    Woods LA; Dolezal O; Ren B; Ryan JH; Peat TS; Poulsen SA
    J Med Chem; 2016 Mar; 59(5):2192-204. PubMed ID: 26882437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors.
    Martinez-Rosell G; Harvey MJ; De Fabritiis G
    J Chem Inf Model; 2018 Mar; 58(3):683-691. PubMed ID: 29481075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of protein-ligand binding constants of a cooperatively regulated tetrameric enzyme using electrospray mass spectrometry.
    Cubrilovic D; Haap W; Barylyuk K; Ruf A; Badertscher M; Gubler M; Tetaz T; Joseph C; Benz J; Zenobi R
    ACS Chem Biol; 2014 Jan; 9(1):218-26. PubMed ID: 24128068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying thermodynamic profiling in lead finding and optimization.
    Klebe G
    Nat Rev Drug Discov; 2015 Feb; 14(2):95-110. PubMed ID: 25614222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.
    Lu H; Iuliano JN; Tonge PJ
    Curr Opin Chem Biol; 2018 Jun; 44():101-109. PubMed ID: 29986213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.